MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Eye, Ocular, Optometry, Ophthalmology, Vision Health Companies
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
Organization & Developments: Apellis
Parents
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
Children
*Apellis Pharmaceuticals is an early stage drug development company focused on peptide drugs in the immunology space.
*Industry: Drug Development Sub-Industry: N/A
*The company is focused on the discovery and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases
2019: Apellis Pharmaceuticals Presses On With Late-Stage Studies After Trial Enrollment Pause
2020: This Biotech Just Topped Alexion's Biggest Moneymaker — And Rocketed_www.investors.com
2021: Apellis Is A Long-Term Name To Own Based On PNH Data Alone
2021: Apellis Pharmaceuticals: Empaveli Approved With A Broad Label
2021: Apellis Plunges On Mixed Phase 3 Results In Geographic Atrophy
2022: Apellis Pharmaceuticals: Approval Is Baked Into Valuation_ seekingalpha.com
2022: Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise_seekingalpha.com
2023: Apellis Pharmaceuticals: Eye Watering, Roller-Coaster Ride In 2023
2023: Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings
2023: Apellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric Bio_ seekingalpha.com
2024: Apellis cites current challenges with Syfovre launch but bright prospects in the long term
2024: Apellis Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain_seekingalpha.com
2024: Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
2024: Apellis: Rare Kidney Disease Data Leads To Possible First To Market_ seekingalpha
2024: Apellis: Saved By The October Data
2024: Apellis: Weighing Syfovre's Rapid Expansion Against Risks In The GA Market (Rating Upgrade)
2024: Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius
2025: Apellis Pharmaceuticals: A Mixed Bag
2026: Biogen ends Apellis research programs, cuts ‘small number’ of roles after $5.6B buyout
Jumps
*Key People: Apellis
Finance & Acquisitions: Apellis